Literature DB >> 16394764

Aberrant methylation of p14ARF gene correlates with poor survival in osteosarcoma.

Joo Han Oh1, Han-Soo Kim, Hyung-Ho Kim, Woo Ho Kim, Sang Hoon Lee.   

Abstract

UNLABELLED: We studied the methylation status of the CpG promoter regions of the p16 and p14 genes, mutations of four exons of the CDKN2A gene, and expressions of their corresponding proteins. Thirty-two frozen osteosarcoma tissues were used for methylation-specific polymerase chain reaction and sequence analysis. Immunohistochemical staining for p16 and p14 proteins was done. The histologic and clinical data were analyzed to find their prognostic implications. The promoter of p16 gene was methylated in 16%, and p14 in 47%. Poor survival was related to methylation of p14. The methylation of p14 correlated with down-regulation of its protein expression. The methylation of p14 showed the highest hazard ratio by multivariate survival analysis. Our data suggest methylation of the CDKN2A gene is the main mechanism of its protein repression. For the p14 gene, methylation of the promoter region was related to repression of p14 protein and poor prognosis. LEVEL OF EVIDENCE: Prognostic study, Level II (retrospective study). See the Guidelines for Authors for a complete description of levels of evidence.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16394764     DOI: 10.1097/01.blo.0000188063.56091.69

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  24 in total

1.  Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations.

Authors:  Yoshiyuki Suehara; Deepu Alex; Anita Bowman; Sumit Middha; Ahmet Zehir; Debyani Chakravarty; Lu Wang; George Jour; Khedoudja Nafa; Takuo Hayashi; Achim A Jungbluth; Denise Frosina; Emily Slotkin; Neerav Shukla; Paul Meyers; John H Healey; Meera Hameed; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2019-06-07       Impact factor: 12.531

2.  Comments on the article of Bu, et al entitled "P16INK4a overexpression and survival in osteosarcoma patients: a meta analysis".

Authors:  Fanxiao Liu; Dongsheng Zhou; Qingyu Zhang; Bomin Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

Review 3.  Epigenetic alterations in osteosarcoma: promising targets.

Authors:  Binghao Li; Zhaoming Ye
Journal:  Mol Biol Rep       Date:  2014-02-06       Impact factor: 2.316

4.  ARF suppresses hepatic vascular neoplasia in a carcinogen-exposed murine model.

Authors:  Stephanie E Busch; Kay E Gurley; Russell D Moser; Christopher J Kemp
Journal:  J Pathol       Date:  2012-05-08       Impact factor: 7.996

Review 5.  P16INK4a overexpression and survival in osteosarcoma patients: a meta analysis.

Authors:  Jie Bu; Hui Li; Li-Hong Liu; Yu-Rong Ouyang; Hong-Bin Guo; Xiao-Yang Li; Tao Xiao
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

6.  Predictive properties of DNA methylation patterns in primary tumor samples for osteosarcoma relapse status.

Authors:  Jeremy M Rosenblum; N Ari Wijetunga; Melissa J Fazzari; Mark Krailo; Donald A Barkauskas; Richard Gorlick; John M Greally
Journal:  Epigenetics       Date:  2015-01-23       Impact factor: 4.528

Review 7.  Translational biology of osteosarcoma.

Authors:  Maya Kansara; Michele W Teng; Mark J Smyth; David M Thomas
Journal:  Nat Rev Cancer       Date:  2014-10-16       Impact factor: 60.716

Review 8.  Therapeutic targets in the ARF tumor suppressor pathway.

Authors:  Anthony J Saporita; Leonard B Maggi; Anthony J Apicelli; Jason D Weber
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

Review 9.  Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate Therapies.

Authors:  James J Morrow; Chand Khanna
Journal:  Crit Rev Oncog       Date:  2015

10.  Genetically engineered mouse models and human osteosarcoma.

Authors:  Alvin Jm Ng; Anthony J Mutsaers; Emma K Baker; Carl R Walkley
Journal:  Clin Sarcoma Res       Date:  2012-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.